Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphomas non-Hodgkin's B-cell

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44412   clinical trials with a EudraCT protocol, of which   7421   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    292 result(s) found for: Lymphomas non-Hodgkin's B-cell. Displaying page 1 of 15.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-000434-47 Sponsor Protocol Number: IM-T-hA20-08 Start Date*: 2008-07-22
    Sponsor Name:Immunomedics, Inc.
    Full Title: A Phase I/II Study of Immunotherapy with Subcutaneous Administered Veltuzumab (hA20) in Patients with CD20+ Non-Hodgkin's Lymphoma or Chronic Lyphocytic Leukemia
    Medical condition: Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029547 Non-Hodgkin's lymphoma LLT
    9.1 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001666-32 Sponsor Protocol Number: APM4083g Start Date*: 2007-12-05
    Sponsor Name:Genentech Inc
    Full Title: A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY OF THE SAFETY,PHARMACOKINETICS, AND EFFICACY OF MULTIPLE DOSES OF APOMAB ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH FOLLICULA...
    Medical condition: Follicular, CD20-Positive B-Cell Non-Hodgkin's Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029593 Non-Hodgkin's lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Completed) GB (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004908-37 Sponsor Protocol Number: IRIS Start Date*: 2011-10-21
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Phase II study on activity and tolerability of intralesional rituximab in relapsed or refractory patients affected by indolentCD-20 positive lymphoma of conjuntiva; evaluation of activity of adding...
    Medical condition: indolent CD-20 positive lymphoma of conjunctiva
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007799-40 Sponsor Protocol Number: 2021/07 Start Date*: 2008-01-28
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Evaluation of intralesional administration of rituximab for treatment of orbital lymphoma
    Medical condition: orbital lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003899 B-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002251-26 Sponsor Protocol Number: CL1-078454-018 Start Date*: 2014-09-08
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Long-term safety study of abexinostat (S 078454) per os given as single-agent in haematological malignancies – Extension study
    Medical condition: Hodgkin's Disease (HD) , Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020206 Hodgkin's disease PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008993 Chronic lymphoid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003749-40 Sponsor Protocol Number: GO27878 Start Date*: 2014-07-07
    Sponsor Name:F. Hoffmann- La Roche Ltd.
    Full Title: A Phase Ib/II, open label study evaluating the safety and pharmacokinetics of GDC-0199 (ABT-199) in combination with Rituximab (R) or Obinutuzumab (G) plus cyclophosphamide, doxorubicin, vincristin...
    Medical condition: B-cell non-hodgkin's lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029601 Non-Hodgkin's lymphoma refractory PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) HU (Completed) CZ (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002666-12 Sponsor Protocol Number: CJBH492A12101 Start Date*: 2020-08-03
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase I/Ib open-label, multi-center dose escalation study of JBH492 in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Non Hodgkin’s Lymphoma (NHL)
    Medical condition: Non-Hodgkins Lymphoma Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005378-73 Sponsor Protocol Number: TBF2012 Start Date*: 2013-01-29
    Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS
    Full Title: Allogeneic Transplantation after a Conditioning with Thiotepa, Busulfan and Fludarabin for the treatment of refractory/early relapsed aggressive B-cell non Hodgkin lymphomas: a Phase II Multi-Cente...
    Medical condition: Refractory/early relapsed aggressive B-cell non Hodgkin lymphomas
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002339-44 Sponsor Protocol Number: IGM-2323-001 Start Date*: Information not available in EudraCT
    Sponsor Name:IGM Biosciences, Inc.
    Full Title: A Phase 1/2 Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas
    Medical condition: Relapsed/Refractory (R/R) Non-Hodgkin lymphomas (NHL)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10025311 Lymphoma (non-Hodgkin's) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) IT (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002989-33 Sponsor Protocol Number: COLPRIT-0000-BAS-0041-I Start Date*: 2023-06-29
    Sponsor Name:Klinikum rechts der Isar der Technischen Universität München
    Full Title: CHEMOKINE RECEPTOR CXCR4-DIRECTED THERANOSTICS OF ADVANCED LYMPHOPROLIFERATIVE CANCERS BY RADIOPEPTIDE-BASED IMAGING AND THERAPY: THE COLPRIT PHASE I/II STUDY
    Medical condition: Indication: Non-Hodgkin lymphomas (NHL) Advanced lymphoproliferative cancers: aggressive B- and T- cell Non-Hodgkin lymphomas (NHL), including heavily pretreated transformed indolent lymphoma (tNHL...
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-003657-87 Sponsor Protocol Number: BCNHL Start Date*: 2007-09-14
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Reduced intensity conditioning with high-dose rituximab followed by allogeneic transplantation of hematopoietic cells for the treatment of relapsed/refractory B-cell non Hodgkin’s lymphomas
    Medical condition: B-cell non-Hodgkin lymphomas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005552-33 Sponsor Protocol Number: APO3585g Start Date*: 2007-06-06
    Sponsor Name:Genentech Inc.
    Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF Apo2L/TRAIL ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB TO SUBJECTS WITH FOLLICULAR AND OT...
    Medical condition: Follicular, CD20+, B-cell non-Hodgkin’s lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029547 Non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013691-47 Sponsor Protocol Number: CL1-78454-001 Start Date*: 2009-12-08
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Phase I/II dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in Hodgkin’s Disease, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia
    Medical condition: Hodgkin's disease (HD) , non-Hodgkin lymphoma (NHL) and chronic lymphocytic Leukaemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020206 Hodgkin's disease LLT
    12.0 10029547 Non-Hodgkin's lymphoma LLT
    12.0 10008993 Chronic lymphoid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-001433-17 Sponsor Protocol Number: Hx-CD20-405 Start Date*: 2006-06-30
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are refractory to rituximab as monotherapy or in...
    Medical condition: Non-Hodgkin Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003899 B-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) DK (Prematurely Ended) DE (Completed) ES (Completed) NL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003828-38 Sponsor Protocol Number: ZEVALIN one shot LNH >60aa Start Date*: 2008-09-01
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE
    Full Title: Yttrium Y90Ibritumomab Tiutexan (Zevalin)as a consolidation treatment for patients with high grade non-Hodgkin's lymphoma aged >60 years.
    Medical condition: High grade B cell non-Hodgkin lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-004097-26 Sponsor Protocol Number: PCI-32765FLR2002 Start Date*: 2013-02-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: An Open-label, Multicenter, Single-arm, Phase 2 Study of PCI-32765 (ibrutinib) in Subjects with Refractory Follicular Lymphoma
    Medical condition: Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005613-19 Sponsor Protocol Number: R-COMP 14 Start Date*: 2007-04-27
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE
    Full Title: R-COMP 14 in elderly patients with high grade non-Hodgkin lymphoma
    Medical condition: Elderly patients with B non-Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016725-34 Sponsor Protocol Number: C18083/2048 Start Date*: 2010-05-21
    Sponsor Name:Cephalon, Inc.
    Full Title: An Open-Label Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL)
    Medical condition: Non-Hodgkin’s Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001103-37 Sponsor Protocol Number: B020999 Start Date*: 2008-10-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An open-label, multicentre, non-randomised, dose-escalating phase I/II study, with a randomized phase II part, to investigate the safety and tolerability of RO5072759 given as monotherapy in patien...
    Medical condition: For the phase I and II parts of the study, patients with CD20+ malignant disease for whom no therapy of higher priority is available and where treatment with an anti-CD20 antibody is deemed appropr...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024340 Leukemia lymphocytic chronic LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025311 Lymphoma (non-Hodgkin's) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002752-33 Sponsor Protocol Number: NL.66760 Start Date*: 2019-01-17
    Sponsor Name:VU University Medical Center
    Full Title: A phase I/II trial towards the safety and efficacy of preemptive vaccination with PD-L silenced, minor histocompatibility antigen UTA2-1 peptide-loaded Dendritic Cells after Allogeneic Stem Cell Tr...
    Medical condition: Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Non hodgkin lymphoma (any grade), Acute myeloid leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    20.0 100000004864 10025311 Lymphoma (non-Hodgkin's) LLT
    20.0 100000004864 10009310 CLL LLT
    20.0 100000004864 10001941 AML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 16 08:36:54 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA